newsmRNA cancer vaccine granted world-first approval10 May 2024 | By Catherine Eckford (European Pharmaceutical Review)Once commercialised, the mRNA therapeutic cancer vaccine will offer a new option to treat advanced Epstein–Barr virus-positive solid tumours and haematologic malignancies.
newsFUJIFILM acquires new cell therapy manufacturing facility5 April 2022 | By Hannah Balfour (European Pharmaceutical Review)FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
newsmRNA vaccine for Epstein-Barr Virus enters Phase I trial6 January 2022 | By Hannah Balfour (European Pharmaceutical Review)The first patient dosed in Phase I study of Moderna’s mRNA-1189, a vaccine candidate for Epstein-Barr Virus (EBV).